EWA
CYTK icon

EverSource Wealth Advisors’s Cytokinetics CYTK Stock Holding History

EverSource Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.8K Sell
902
-646
-42% -$46.4K ﹤0.01% 1526
2026
Q1 		$102K Buy
1,548
+549
+55% +$34.9K ﹤0.01% 1416
2025
Q4 		$63.5K Buy
999
+110
+12% +$6.84K ﹤0.01% 1590
2025
Q3 		$48.9K Buy
889
+123
+16% +$5.07K ﹤0.01% 1725
2025
Q2 		$25.3K Buy
766
+673
+724% +$23.4K ﹤0.01% 2113
2025
Q1 		$3.74K Buy
93
+42
+82% +$1.93K ﹤0.01% 2639
2024
Q4 		$2.4K Buy
51
+13
+34% +$675 ﹤0.01% 2646
2024
Q3 		$2.01K Sell
38
-20
-34% -$1.11K ﹤0.01% 2548
2024
Q2 		$3.42K Buy
58
+7
+14% +$423 ﹤0.01% 2356
2024
Q1 		$3.13K Buy
51
+14
+38% +$1.08K ﹤0.01% 2230
2023
Q4 		$3.09K Sell
37
-57
-61% -$2.06K ﹤0.01% 2042
2023
Q3 		$2.77K Buy
94
+47
+100% +$1.56K ﹤0.01% 1910
2023
Q2 		$1.53K Buy
47
+35
+292% +$1.29K ﹤0.01% 2102
2023
Q1 		$422 Buy
+12
New +$490 ﹤0.01% 2261

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's CYTK Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Cytokinetics (CYTK) stake by 42% in Q2 2026, selling an estimated $46.4K and leaving 902 shares worth $76.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

EverSource Wealth Advisors first reported a position in CYTK in Q1 2023 and has held it in 14 quarters since. The position peaked at $102K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • EverSource Wealth Advisors held 902 shares of Cytokinetics worth $76.8K as of Q2 2026.
  • EverSource Wealth Advisors sold 646 Cytokinetics shares in Q2 2026, an estimated $46.4K.
  • Cytokinetics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1526 holding.
  • EverSource Wealth Advisors first reported a position in Cytokinetics in Q1 2023 and has held it in 14 quarters since.
  • EverSource Wealth Advisors's Cytokinetics position peaked at $102K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.